¼¼°èÀÇ Á¤¹Ð °Ô³ð °Ë»ç ½ÃÀå º¸°í¼­(2025³â)
Precision Genomic Testing Global Market Report 2025
»óǰÄÚµå : 1811009
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 250 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,308,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,117,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,927,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Á¤¹Ð °Ô³ð °Ë»ç ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ±Þ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù. 2029³â¿¡´Â CAGR 11.4%·Î 231¾ï 1,000¸¸ ´Þ·¯·Î ¼ºÀåÇÕ´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ¼ºÀåÀº Á¤¹Ð Á¾¾çÇÐ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Èñ±ÍÁúȯ Áø´Ü¿¡ ´ëÇÑ °ü½É Áõ°¡, Áý´Ü À¯ÀüüÇÐ ±¸»ó¿¡ ´ëÇÑ ÅõÀÚ È®´ë, ¸ÖƼ¿À¹Í½º Á¢±Ù¹ý Ȱ¿ë È®´ë, ºñħ½ÀÀû »êÀü °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ±âÀÎÇÏ´Â °ÍÀ¸·Î ºÐ¼®µË´Ï´Ù. ÀÌ ±â°£ Áß ¿¹»óµÇ´Â ÁÖ¿ä µ¿ÇâÀ¸·Î´Â Â÷¼¼´ë ½ÃÄö½Ì ±â¼úÀÇ ¹ßÀü, ¾×ü»ý°Ë ±â¼úÀÇ Çõ½Å, À¯Àüü ºÐ¼®¿¡ ÀΰøÁö´ÉÀÇ ÅëÇÕ, ¸ÖƼ¿À¹Í½º µ¥ÀÌÅÍ ºÐ¼®ÀÇ °³¼±, ¼ÒºñÀÚ Á÷Á¢ À¯ÀüÀÚ °Ë»ç ¸ðµ¨ÀÇ ÁøÈ­ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.

À¯Àü¼º ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ÇâÈÄ ¼ö³â°£ Á¤¹ÐÀ¯Àüü°Ë»ç ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯Àü¼º ÁúȯÀº °³ÀÎÀÇ DNA ÀÌ»ó¿¡ ÀÇÇØ ¹ß»ýÇÏ´Â º´À¸·Î ´ÜÀÏ À¯ÀüÀÚÀÇ º¯ÀÌ, ¿©·¯ À¯ÀüÀÚÀÇ º¯ÀÌ, ¿°»öüÀÇ ±¸Á¶Àû ¶Ç´Â ¼öÄ¡Àû º¯È­¸¦ ¼ö¹ÝÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ À¯Àü¼º Áúȯ Áõ°¡´Â »ê¸ðÀÇ ¿¬·ÉÀÌ ³ô¾ÆÁö´Â °ÍÀÌ ÁÖ¿ä ¿øÀÎÀ̸ç, °í·ÉÀÇ »ê¸ð´Â ´Ù¿îÁõÈıº°ú °°Àº ¿°»öü ÀÌ»ó Àڳฦ ³ºÀ» À§ÇèÀÌ ³ô±â ¶§¹®ÀÔ´Ï´Ù. Á¤¹Ð °Ô³ð °Ë»ç´Â ƯÁ¤ À¯ÀüÀÚ º¯À̸¦ È®ÀÎÇÔÀ¸·Î½á À¯Àü¼º ÁúȯÀÇ Á¶±â ¹ß°ß°ú Á¤È®ÇÑ Áø´ÜÀ» °¡´ÉÇÏ°Ô Çϰí, Ç¥ÀûÈ­µÈ °³ÀÔ°ú ¸ÂÃã Ä¡·á °èȹÀ» Áö¿øÇÕ´Ï´Ù. ¿¹¸¦ µé¾î 2025³â 5¿ù ¿µ±¹¿¡ º»ºÎ¸¦ µÐ µî·Ï ÀÚ¼±´ÜüÀÎ Áø ÇÇÇýº(Gene People)´Â À¯ÀüÁúȯÀÌ ¾î¸°ÀÌ 25¸í Áß 1¸í¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡¸ç, ¿µ±¹¿¡¼­´Â 240¸¸ ¸í ÀÌ»óÀÌ ¿µÇâÀ» ¹Þ°í ÀÖ´Ù°í º¸°íÇß½À´Ï´Ù. ¶ÇÇÑ ¿µ±¹¿¡¼­´Â ¸Å³â ¾à 3¸¸ ¸íÀÇ ½Å»ý¾Æ¿Í ¾î¸°À̰¡ À¯Àüº´ Áø´ÜÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ±× °á°ú À¯Àü¼º ÁúȯÀÇ ¹ßº´·üÀÌ ³ô¾ÆÁö¸é¼­ Á¤¹ÐÀ¯Àüü°Ë»ç ½ÃÀåÀÇ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

Á¤¹ÐÀ¯Àüü°Ë»ç ½ÃÀåÀÇ ±â¾÷Àº ¾ÏÀÇ Á¶±â ¹ß°ß°ú Áø´Ü Á¤È®µµ¸¦ ³ôÀ̱â À§ÇØ Ãʹਵµ ¼øÈ¯Á¾¾ç DNA ºÐ¼® µî ÷´Ü ±â¼ú °³¹ß¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °Ë»ç¹ýÀº Ç÷·ù¿¡ Á¸ÀçÇÏ´Â Á¾¾ç À¯·¡ DNAÀÇ ¹Ì¼¼ÇÑ ´ÜÆíÀ» ½Äº°ÇÒ ¼ö ÀÖÀ¸¸ç, ¾Ï°ú °ü·ÃµÈ À¯ÀüÀÚ º¯À̸¦ º¸´Ù Á¶±â¿¡, º¸´Ù Á¤È®ÇÏ°Ô °ËÃâÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2025³â 4¿ù ¹Ì±¹ÀÇ ÀÓ»ó À¯ÀüÀÚ °Ë»ç ȸ»çÀÎ Natera Inc.´Â Ãʹਵµ Signatera À¯Àüü ºÐÀÚ ÀÜÁ¸ º´º¯ °Ë»ç¸¦ Ãâ½ÃÇß½À´Ï´Ù. ÀÌ °Ë»ç´Â ȯÀÚÀÇ Á¾¾ç DNA¿Í ÀÏÄ¡ÇÏ´Â Á¤»ó DNAÀÇ ÀüÀåÀ¯Àüü ½ÃÄö½ÌÀ» Àû¿ëÇÏ¿© °³Àκ° ¸ÂÃ㠺м®¹ýÀ» ¸¸µé¾î 100¸¸ºÐÀÇ 1À̶ó´Â ±ØÈ÷ ³·Àº ³óµµÀÇ ¼øÈ¯ Á¾¾ç DNA¸¦ °ËÃâÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ³ôÀº ¹Î°¨µµ´Â ¾ÏÀÇ Àç¹ßÀ» Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖÀ¸¸ç, ¿©·¯ ¾ÏÁ¾¿¡ ´ëÇÑ Ä¡·á °èȹ°ú ȯÀÚ Ä¡·á¸¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå ½ÃÀåÀÇ Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå : ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ª ÀüÀï°ú °ü¼¼ ¹× Covid¿Í ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°¡¤±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ´ë±â¾÷°ú Çõ½ÅÀû ±â¾÷

Á¦32Àå ¼¼°èÀÇ ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÇÕº´°ú Àμö

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Precision genomic testing involves the use of advanced genetic analysis to detect specific DNA variations or mutations that impact an individual's risk of disease, diagnosis, prognosis, or treatment response. This approach supports personalized healthcare by enabling tailored prevention strategies, therapeutic interventions, and drug selection based on a person's unique genetic profile.

The key products and services in precision genomic testing include consumables, equipment, and services. Consumables are items intended for single or repeated use and are depleted through routine procedures, examples include laboratory reagents and medical supplies. The testing employs a variety of advanced technologies, such as next-generation sequencing (NGS), polymerase chain reaction (PCR), microarray technology, Sanger sequencing, and CRISPR-associated systems. It is applied across multiple areas, including oncology, cardiovascular diseases, neurological disorders, reproductive health, rare diseases, and more. End users include hospitals and clinics, diagnostic laboratories, research and academic institutions, among others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The precision genomic testing market research report is one of a series of new reports from The Business Research Company that provides precision genomic testing market statistics, including precision genomic testing global market size, regional shares, competitors with precision genomic testing market share, detailed precision genomic testing market segments, market trends and opportunities, and any further data you may need to thrive in the precision genomic testing industry. The precision genomic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The precision genomic testing market size has grown rapidly in recent years. It will grow from $13.44 billion in 2024 to $15.00 billion in 2025 at a compound annual growth rate (CAGR) of 11.6%. Growth in the historic period can be attributed to the increasing availability of direct-to-consumer genetic testing, rising collaborations between pharmaceutical and diagnostic companies, a heightened focus on preventive healthcare, greater adoption of companion diagnostics, and growing awareness of the importance of early disease detection.

The precision genomic testing market size is expected to see rapid growth in the next few years. It will grow to $23.11 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. Growth in the forecast period can be attributed to the rising demand for precision oncology solutions, increased focus on rare disease diagnostics, growing investment in population genomics initiatives, expanded use of multi-omics approaches, and the rising demand for non-invasive prenatal testing. Key trends expected during this period include advancements in next-generation sequencing technologies, innovations in liquid biopsy techniques, integration of artificial intelligence in genomic analysis, improvements in multi-omics data interpretation, and the evolution of direct-to-consumer genetic testing models.

The increasing prevalence of genetic disorders is anticipated to drive the growth of the precision genomic testing market in the coming years. Genetic disorders are medical conditions caused by abnormalities in an individual's DNA, which may involve mutations in a single gene, multiple genes, or structural or numerical changes in chromosomes. This rise in genetic disorders is largely attributed to the increasing maternal age, as older mothers face a higher risk of having children with chromosomal abnormalities, such as Down syndrome. Precision genomic testing allows for early detection and accurate diagnosis of genetic disorders by identifying specific genetic mutations, which supports targeted interventions and personalized treatment plans. For example, in May 2025, Gene People, a UK-based registered charity, reported that genetic conditions affect approximately 1 in 25 children, impacting over 2.4 million individuals in the UK. Additionally, around 30,000 newborns and children are diagnosed with a genetic condition each year in the UK. As a result, the rising incidence of genetic disorders is fueling the growth of the precision genomic testing market.

Companies in the precision genomic testing market are focusing on the development of advanced technologies, such as ultra-sensitive circulating tumor DNA assays, to improve early cancer detection and diagnostic accuracy. These assays are capable of identifying minute fragments of tumor-derived DNA present in the bloodstream, which enables earlier and more precise detection of genetic mutations associated with cancer. For instance, in April 2025, Natera Inc., a US-based clinical genetic testing company, launched the ultra-sensitive Signatera genome molecular residual disease test. This test applies whole genome sequencing of both the patient's tumor and matched normal DNA to create a personalized assay, enabling detection of circulating tumor DNA at extremely low concentrations-down to 1 part per million. Such high sensitivity allows for earlier detection of cancer recurrence, improving treatment planning and patient care across multiple cancer types.

In November 2022, Myriad Genetics Inc., a US-based healthcare company, acquired Gateway Genomics LLC for $67.5 million. This acquisition was aimed at strengthening Myriad Genetics' women's health portfolio by expanding into the early prenatal testing segment. The addition of Gateway Genomics' SneakPeek early gender DNA test broadens Myriad's offerings in the consumer genetic testing space. Gateway Genomics LLC, based in the US, specializes in the development of genetic-based tests for consumers, particularly focused on early prenatal applications.

Major players in the precision genomic testing market are Roche Diagnostics International AG, Thermo Fisher Scientific Inc., Danaher Corporation, Agilent Technologies Inc., Illumina Inc., Revvity Inc., QIAGEN N.V., Exact Sciences Corporation, Natera Inc., Myriad Genetics Inc., GenScript Biotech Corporation, Fulgent Genetics Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Guardant Health Inc., Ambry Genetics Corporation, Color Health Inc., Pacific Biosciences, Eurofins Genomics LLC, and Precision Genetics.

North America was the largest region in the precision genomic testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in precision genomic testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the precision genomic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The precision genomic testing market consists of revenues earned by entities by providing services such as gene panel testing, whole genome and exome analysis, pharmacogenomics testing, cancer genomics profiling, hereditary disease screening, and bioinformatics-driven interpretation of genetic data. The market value includes the value of related goods sold by the service provider or included within the service offering. The precision genomic testing market also includes sales of hybridization buffers and enzymes, targeted gene panels, library preparation kits, genomic data compression tools, and rare mutation detection kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Precision Genomic Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on precision genomic testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for precision genomic testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The precision genomic testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Precision Genomic Testing Market Characteristics

3. Precision Genomic Testing Market Trends And Strategies

4. Precision Genomic Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Precision Genomic Testing Growth Analysis And Strategic Analysis Framework

6. Precision Genomic Testing Market Segmentation

7. Precision Genomic Testing Market Regional And Country Analysis

8. Asia-Pacific Precision Genomic Testing Market

9. China Precision Genomic Testing Market

10. India Precision Genomic Testing Market

11. Japan Precision Genomic Testing Market

12. Australia Precision Genomic Testing Market

13. Indonesia Precision Genomic Testing Market

14. South Korea Precision Genomic Testing Market

15. Western Europe Precision Genomic Testing Market

16. UK Precision Genomic Testing Market

17. Germany Precision Genomic Testing Market

18. France Precision Genomic Testing Market

19. Italy Precision Genomic Testing Market

20. Spain Precision Genomic Testing Market

21. Eastern Europe Precision Genomic Testing Market

22. Russia Precision Genomic Testing Market

23. North America Precision Genomic Testing Market

24. USA Precision Genomic Testing Market

25. Canada Precision Genomic Testing Market

26. South America Precision Genomic Testing Market

27. Brazil Precision Genomic Testing Market

28. Middle East Precision Genomic Testing Market

29. Africa Precision Genomic Testing Market

30. Precision Genomic Testing Market Competitive Landscape And Company Profiles

31. Precision Genomic Testing Market Other Major And Innovative Companies

32. Global Precision Genomic Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Precision Genomic Testing Market

34. Recent Developments In The Precision Genomic Testing Market

35. Precision Genomic Testing Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â